慢性心力衰竭患者NT-proBNP下降率对疗效及预后的评估价值

目的探讨血浆氨基末端脑利钠肽前体(NT-proBNP)下降率对慢性心力衰竭(CHF)患者疗效及预后的评估价值。方法连续入选2011年10月至2012年6月在包头市中心医院心内科住院心功能(NYHA分级)Ⅲ~Ⅳ级的CHF患者120例,根据血浆NT-proBNP下降率分为两组,其中A组64例(血浆NT-pro BNP下降率≥50%);B组56例(血浆NT-proBNP下降率50%)。比较两组患者的一般临床资料(包括年龄、性别、体重指数,合并症有无高血压病、糖尿病、高脂血症)、出院时疗效及在出院后6个月内再住院率及死亡率。结果两组患者在出院时疗效评估,A组患者治疗效果良好比例为87.5%,显著高于B组患者(71.4%),差异有统计学意义(P0.05)。两组患者出院后随访6个月时,A组患者再住院率为6.3%,显著低于B组患者再住院率(21.4%);A组患者死亡率为1.6%,显著低于B组患者死亡率(12.5%),差异均有统计学意义(P0.05)。结论 NT-proBNP的下降率对判断慢性心力衰竭患者的住院治疗效果及预后有帮助。

Evaluation value of NT-proBNP descent rate to curative effect and prognosis in patients with chronic ;heart failure

Objective To investigate the evaluation value of plasma NT-proBNP descent rate to curative effect and prognosis in patients with chronic heart failure （CHF）. Methods CHF patients （n=120） with NYHA grading from grade III to grade IV of were chosen from the Central Hospital of Baotou City from Oct. 2011 to Jun. 2012, and then divided into group A （n=64, NT-proBNP descent rate≥50%） and group B （n=56, NT-proBNP descent rate〈50%） according to NT-proBNP descent rate. The general data age, sex, body mass index （BMI）, and complications （hypertension, diabetes and hyperlipidemia）], curative effect at discharge time, and readmission and mortality after discharge for 6 months were compared between 2 groups. Results The effective rate was 87.5%in group A and 71.4%in group B （P〈0.05） at discharge time. The readmission rate was 6.3%in group A and 21.4%in group B, and mortality was 1.6%in group A and 12.5%in group B （P〈0.05） after discharge for 6 months. Conclusion NT-proBNP descent rate is helpful to judge the curative effect and prognosis for hospitalized CHF patients.